Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?

Annals of Oncology

Volumn 8, Issue 7, 1997, Pages 637-641

  Edmonson, J H ^a   Long, H J ^a   Kvols, L K ^a   Mann, B S ^a   Grill, J P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Cisplatin; Doxorubicin; Mitomycin; Molgramostim; Sarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; IFOSFAMIDE; MITOMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; HUMAN; HYPOTHESIS; INTRAVENOUS DRUG ADMINISTRATION; PATIENT COMPLIANCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SARCOMA; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT PLANNING;

ADULT; ANTINEOPLASTIC AGENTS; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; MESNA; MITOMYCINS; RECOMBINANT PROTEINS; SARCOMA; SURVIVAL ANALYSIS;

EID: 0030761138     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008292010062     Document Type: Article

References (20)

1. Edmonson JH. Needed: Qualitative improvement in antisarcoma therapy. J Clin Oncol (1995) 13: 1531-3 (Editorial).
2. Tursz T, Verweij J, Judson I et al. EORTC Soft Tissue and Bone Sarcoma Group. Is high-dose chemotherapy of interest in advanced soft tissue sarcomas? An EORTC randomized phase III trial. Proc Am Soc Clin Oncol 1996; 15: 337.
3. Steward WP, Verweij J, Spooner D et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: A study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1993; 11: 15-21.
4. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11: 1269-75.
5. Edmonson JH, Long HJ, Kvols LK. Cytotoxic drugs plus subcutaneous granulocyte macrophage colony stimulating factor: Can molgramostim enhance antisarcoma therapy? J Natl Cancer Inst 1994; 86: 312-4.
6. Edmonson JH, Hartmann LC, Long HJ et al. Granulocyte macrophage-colony stimulating factor, preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin. Cancer 1992; 70: 2529-39.
7. Dorr RT. Clinical properties of yeast-derived versus Escherichia coli-derived granulocyle macrophage-colony stimulating factor. Clin Ther 1993; 15: 19-29.
8. Gasson JC, Weisbart RH, Kaufman SE et al. Purified human granulocyte-macrophage colony-stimulating factor: Direct action on neutrophils. Science 1984; 226: 1339-42.
9. Steff CA. Hematopoietic growth factors. J Clin Invest 1985; 79: 1549-57.
10. Mayer P, Lam C, Obenaus H et al. Recombinant human GM-CSF induces leukocytosis and activates peripheral blood polymorphonuclear neutrophils in nonhuman primates. Blood 1987; 70: 206-13.
11. Moonen P, Mermod JJ, Ernst JF et al. Increased biological activity of deglycosylated recombinant human granulocyte/macrophage-colony stimulating factor produced by yeast or animal cells. Proc Natl Acad Sci USA 1987; 84: 4428-31.
12. Cebon J, Nicola N, Ward M et al. Granulocyte-macrophage colony stimulating factor from human lymphocytes: the effect of glycosylation on receptor binding and biological activity. J Biol Chem 1990; 265: 4483-91.
13. Donahue RE, Wang EA, Kaufman RJ et al. Effects of N-linked carbohydrate on the in vivo properties of human GM-CSF. Cold Spring Harbor Symposia on Quantitative Biology 1986; 51: 685-92.
14. Clark SC, Kamen R. The human hematopoietic colony-stimulating factors. Science 1987; 236: 1229-37.
15. Kaushansky K, O'Hara PJ, Hart CE et al. Role of carbohydrate in the function of human granulocyte macrophage-colony stimulating factor. Biochemistry 1987; 26: 4861-7.
16. Diederichs K, Boone T, Karplus PA. Novel fold and putative receptor binding site of granulocyte macrophage-colony stimulating factor. Science 1991; 254: 1779-82.
17. Cannistra SA, Vellenga E, Groshek P et al. Human granulocyte-monocyte colony-stimulating factor and interleukin-3 stimulate monocyte cytotoxicity through a tumor necrosis factor dependent mechanism. Blood 1988; 71: 672-6.
18. Heidenreich S, Gong JH, Schmidt A et al. Macrophage activation by granulocyte/macrophage colony stimulating factor; priming for enhanced released of tumor necrosis factor 2 and prostaglandin E2. J Immunol 1989; 143: 1198-205.
19. Wing EJ, Magee M, Whiteside TL et al. Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor 2 and interferon in cancer patients. Blood 1989; 73: 643-6.
20. Steward WP, Scarffe JH, Austin R et al. Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions - a phase I dose-toxicity study. Br J Cancer 1989; 59: 142-5.